Enhanced patient selection with quantitative continuous scoring of PD-L1 expression for IO treatment in metastatic NSCLC



Summary

Quantitative, continuous scoring of PD-L1 expression offers improved patient selection for immunotherapy (IO) treatment in metastatic non-small cell lung cancer (NSCLC). Traditional immunohistochemistry (IHC) relies on semi-quantitative methods and arbitrary cutoffs, limiting precision. Continuous scoring provides a more nuanced understanding of PD-L1 levels, potentially identifying patients who might benefit from IO but are missed by conventional methods. This approach enhances the ability to predict treatment response, leading to better patient outcomes and resource allocation by tailoring therapy to those most likely to benefit. Ultimately, this leads to more effective personalized medicine in NSCLC.

Read more…

Credits: Source

This post is part of “Science/Immunology News”, Follow for more…!!!